Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLD vs Conventional Doxorubicin in Neoadjuvant Breast Cancer Treatment
NCT02953184Phase 2Unknown
- Sponsor
- Jilin University
- Start
- Nov 2016
- Primary completion
- Nov 2019
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pegylated liposomal doxorubicin in breast cancer (2 arms), sponsored by Jilin University. Primary endpoint: Pathological Complete Response at 26 weeks. Status: unknown.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02953184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02953184.